A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost

Clinical Rheumatology

Volumn 28, Issue 7, 2009, Pages 807-813

  Caramaschi, Paola ^a   Martinelli, Nicola ^a   Volpe, Alessandro ^a   Pieropan, Sara ^a   Tinazzi, Ilaria ^a   Patuzzo, Giuseppe ^a   Mahamid, Helal ^a   Bambara, Lisa Maria ^a   Biasi, Domenico ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Digital ulcers; Iloprost; Smoking; Systemic sclerosis

Indexed keywords

CORTICOSTEROID; ILOPROST; SCL 70 ANTIBODY;

ADULT; ARTICLE; DELAYED DIAGNOSIS; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; ISCHEMIC DIGITAL ULCER; JOINT CONTRACTURE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SKIN DISEASE; SMOKING HABIT; SYSTEMIC SCLEROSIS; THERAPY DELAY; TREATMENT DURATION; ULCER;

FEMALE; FINGERS; HUMANS; ILOPROST; ISCHEMIA; MALE; MIDDLE AGED; RAYNAUD DISEASE; RISK FACTORS; ROC CURVE; SCLERODERMA, SYSTEMIC; SKIN; ULCER; VASODILATOR AGENTS;

EID: 67349203559     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1155-6     Document Type: Article

References (30)

1. Marasini B, Cugno M, Bassani C, Stanzani M, Bottasso B, Agostoni A (1992) Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 11:375-382
2. Ferri C, Valentini G, Cozzi F et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81:139-153
3. Mawdsley AH (2006) Patient perception of UK scleroderma services - results of an anonymous questionnaire. Rheumatology 45:1573
4. Rodnan G, Myerowitz R, Justh G (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 59:393-408
5. Denton C, Korn J (2003) Digital ulceration and critical digital ischemia in scleroderma. Scleroderma Care Res 1:12-16
6. Nihtyanova SI, Brough GM, Black CM, Denton CP (2008) Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 67:120-123
7. Walker UA, Tyndall A, Czirjak L et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 66:754-763
8. Herrick AL, Heaney M, Hollis S, Jayson MI (1994) Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia. Ann Rheum Dis 53:540-542
9. Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ (1992) Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis Rheum 35:688-693
10. Ostojic P, Damjanov N, Pavlov-Dolijanovic S, Radunovic G (2004) Peripheral vasculopathy in patients with systemic sclerosis: Difference in limited and diffuse subset of disease. Clin Hemorheol Microcirc 31:281-285
11. Chung L, Fiorentino D (2006) Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 5:125-128
12. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
13. LeRoy EC, Black CM, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 15:202-205
14. Akesson A, Fiori G, Krieg T, van den Hoogen FHJ, Seibold JR (2002) Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 21(Suppl 29):S5-8
15. Cutolo M, Sulli A, Pizzorni C, Accardo S (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27:155-160
16. Wigley FM, Wise A, Seibold J et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120:199-206
17. Wigley FM, Seibold J, Wise A, McCloskey D, Dole WP (1992) Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19:1407-1414
18. Torley HJ, Madhok R, Capell HA et al (1991) A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 50:800-804
19. Pope J, Fenlon D, Thompson A et al (2000) Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000953
20. Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R (2001) Novel mode of action of iloprost: In vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 65:73-83
21. Filaci G, Cutolo M, Scudeletti M et al (1999) Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology 38:992-996
22. Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R (1997) Cytokine production in scleroderma patients: Effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 15:135-141
23. Stratton R, Shiwen X, Martini G et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108:241-250
24. Caramaschi P, Volpe A, Tinazzi I, Bambara LM, Carletto A, Biasi D (2006) Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results. Rheumatol Int 27:203-205
25. Korn JH, Mayes M, Matucci-Cerinic M et al (2004) Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50:3985-3893
26. Harrison BJ, Silman AJ, Hider SL, Herrick AL (2002) Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum 46:3312-3316
27. Powell JT (1998) Vascular damage from smoking: Disease mechanisms at the arterial wall. Vasc Med 3:21-28
28. Veale DJ, Collidge TA, Belch JJ (1995) Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 54:853-855
29. Ho M, Veale D, Eastmond C, Nuki G, Belch J (2000) Macrovascular disease and systemic sclerosis. Ann Rheum Dis 59:39-43
30. Simeon CP, Armadans L, Fonollosa V et al (2003) Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 42:71-75